Is ARGX or ATRA more undervalued in 2026?

CirclFi compares argenx SE (ARGX) and Atara Biotherapeutics, Inc. (ATRA) using 13 institutional-grade valuation models. ARGX has a Quality of Company score of 2.0/10 while ATRA scores 4.8/10.

Which is a better buy — ARGX or ATRA?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do ARGX and ATRA valuations compare?

ARGX at $835.99 and ATRA at $10.51 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

ARGX vs ATRA Valuation Comparison 2026 — Intrinsic Value Analysis

ARGX

Biological Products, (No Diagnostic Substances)

argenx SE

Quality

2.0

out of 10

Value Trap

—

Price

$835.99

Last close

Models

13/13

Active

ATRA

Biological Products, (No Diagnostic Substances)

Atara Biotherapeutics, Inc.

Quality

4.8

out of 10

Value Trap

SAFE

Price

$10.51

Last close

Models

10/13

Active

Model-by-Model Comparison

Model	Type	ARGX Fair Value	ARGX Upside	ATRA Fair Value	ATRA Upside
Bayesian DCF	Intrinsic	$269.52	-67.8%	$1.88	-82.2%
Earnings Power Value	Intrinsic	$363.38	-53.4%	$49.72	+496.1%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for ARGX vs ATRA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ARGX vs ATRA — Which Stock Is More Undervalued?

ATRA scores higher with a 4.8/10 quality rating vs ARGX's 2.0/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing argenx SE (ARGX) and Atara Biotherapeutics, Inc. (ATRA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ARGX currently trades at $835.99 with a QOC of 2.0/10, while ATRA trades at $10.51 with a QOC of 4.8/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).